Year: 2023

Pressure BioSciences’ Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately

PBIO Acknowledges Rapidly Emerging Demand Potential for UltraShear Nanoemulsions for Transformation of Diverse Major Markets, with Recently Announced Readiness and...

Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d’une conférence web le 26 septembre à 14 h 00 CET

Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14...

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...

ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company...

error: Content is protected !!